demonstrated that BC patients receiving chemotherapy will activate the EZH2/STAT3 pathway in BC cells, which then secrete miR-378a-3p and miR-378d rich in sEVs, and chemotherapy-surviving BC cells will prompting activation of the WNT/β-catenin and Notch stem cell pathways and subsequently leading to drug resistance (127). The gene discussed is EZH2; the disease is breast cancer.